Performance in Initiating Clinical Trials Q4 2016-2017 70 day benchmark, valid application to first participant recruited NHS Permission Studies only

Research Ethics Committee Number	IRAS Number	Name of Trial	Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met	Source of Delay	Comments
15/SC/0432		A Randomized, Double-blind, Multicenter, Active- controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression - TRANSFORM	28/03/2016		No	Neither NHS or	No eligible patients seen due to strict eligibility criteria. The sponsor recognised study is difficult to recruit to for all sites and has extended recruitment and introduced a new recruitment tool.
15/SC/0434		An open-label, long-term, safety and efficacy study of intranasal Esketamine in Treatment-resistant Depression in Adults SUSTAIN-2	28/03/2016	17/06/2016	No	Neither NHS or	No eligible patients seen due to strict eligibility criteria. This study has been difficult to recruit to for all sites. Sponsor has initiated a new recruitment tool.
15/NE/0269		A Parallel-Group, Double Blind Long Term Safety Trial of MK-8931 in Subjects with Alzheimer's Disease. (Protocol No. MK-8931-017-12) - EPOCH Ext					A sponsor error meant that the study site was not able to start recruitment despite being ready.
16/NS/0006		Preliminary Evaluation of Lithium as a GSK-3 inhibitor in mild cognitive impairment Antibiotics for lower Respiritory Tract Infection in Children	05/10/2016	13/12/2016	Yes		
15/SW/0300 13/NW/0621		presenting in Primary Care The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a doubleblind randomised placebo controlled trial	30/03/2017		NA No	NHS or	This is a seasonal flu study and therefore recruitment of potential participants is dependent on patients presenting with flulike symptoms.